Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 2, 2025Open Access

Loss of Measles, Mumps, and Rubella Immunity in Pediatric Cancer Survivors Following Chemotherapy

View Full Paper
Ask AI
Bookmark
Share

Authors

KNKanokan NakasuwanCTChonnamet TechasaensiriMahidol UniversitySCSujittra ChaisavaneeyakornMahidol University

Discussion

Loading...

Member takes

Implication

Observational study assessed MMR immunity in pediatric cancer survivors, indicating significant antibody loss.

Key Points

  • 79.6% of pediatric cancer survivors were seronegative for at least one MMR component.
  • Measles seronegativity was notably linked to a longer interval since chemotherapy, exceeding 5 years.
  • Older age at receiving the second MMR dose was associated with increased measles seronegativity.
  • Findings advocate for routine revaccination without prior serologic testing in survivorship care.

Cite This Study

Nakasuwan et al. (2025) studied this question.

synapsesocial.com/papers/68de6f3183cbc991d0a220f6https://doi.org/10.21203/rs.3.rs-7461224/v1
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy2004 · 148 citations
  2. 2Humoral immune response of childhood acute lymphoblastic leukemia survivors against the measles, mumps, and rubella vaccination2018 · 28 citations
  3. 3Executive Summary: 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host2014 · 1,047 citations
  4. 4Seroprevalence of Measles-, Mumps-, and Rubella-specific antibodies in the German adult population – cross-sectional analysis of the German Health Interview and Examination Survey for Adults (DEGS1)2021 · 34 citations
  5. 5Immune Recovery in Children With Malignancy After Cessation of Chemotherapy1998 · 109 citations